Effect of dupilumab on airway structure and function in COPD: phase 4 AEOLUS trial protocol

Background Up to 40% of patients with COPD have type 2 inflammation. Interleukin (IL)-4/IL-13 are key drivers of type 2 inflammation, contributing to mucus plug formation and reduced clearance, which are linked to worse disease outcomes. Dupilumab, an anti-IL4Rα antibody, has shown efficacy and safety in patients with COPD and type 2 inflammation. However, the mechanisms driving exacerbation reductions and improvements in lung function and symptoms remain unclear. We present the phase 4 AEOLUS trial design that will evaluate the impact of dupilumab on mucus plugs and airway characteristics in those patients. Methods AEOLUS ( clinicaltrials.gov identifier NCT07053423 ), a phase 4, randomised, double-blind, placebo-controlled, multinational trial, will randomise 218 former or current smokers (aged 40–85 years) with COPD on inhaled background therapy (2:1) to dupilumab 300 mg or placebo every 2 weeks for 24 weeks. Key inclusion criteria were post-bronchodilator forced expiratory volume in 1 s (FEV 1 ) to forced vital capacity ratio <0.70, FEV 1 30% predicted to <80% pred, screening blood eosinophil count ≥300 cells·μL −1 or ≥150 cells·μL −1 with a history of ≥300 cells·μL −1 in the previous year, two or more moderate exacerbations or one or more severe exacerbations in the previous year and mucus plug score ≥3 on computed tomography (CT). The primary end-point was week 24 change from baseline in CT-evaluated mucus plug score. Secondary end-points were week 24 change from baseline in mucus plug volume, distal airway wall thickness, oscillometry parameters and safety. Conclusion AEOLUS will evaluate the effect of dupilumab on airway characteristics (mucus, resistance and remodelling) in patients with COPD and type 2 inflammation.

Authors

Publication Details

Journal
ERJ Open Research
Published
2026-11-19
DOI
https://doi.org/10.1183/23120541.01241-2026
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of dupilumab on airway structure and function in COPD: phase 4 AEOLUS trial protocol

Hashem Awad, Danen Mootoosamy Cunoosamy, Alejandro A. Díaz, Surya Prakash Bhatt et al.
ERJ Open Research
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Effect of dupilumab on airway structure and function in COPD: phase 4 AEOLUS trial protocol

Hashem Awad, Danen Mootoosamy Cunoosamy, Alejandro A. Díaz, Surya Prakash Bhatt, Parameswaran K. Nair, Mena Soliman, Sarah Svenningsen, George R. Washko, Grace Párraga, Mei Zhang, Christopher E Brightling, Jadwiga A. Wedzicha
article en

Abstract

Background Up to 40% of patients with COPD have type 2 inflammation. Interleukin (IL)-4/IL-13 are key drivers of type 2 inflammation, contributing to mucus plug formation and reduced clearance, which are linked to worse disease outcomes. Dupilumab, an anti-IL4Rα antibody, has shown efficacy and safety in patients with COPD and type 2 inflammation. However, the mechanisms driving exacerbation reductions and improvements in lung function and symptoms remain unclear. We present the phase 4 AEOLUS trial design that will evaluate the impact of dupilumab on mucus plugs and airway characteristics in those patients. Methods AEOLUS ( clinicaltrials.gov identifier NCT07053423 ), a phase 4, randomised, double-blind, placebo-controlled, multinational trial, will randomise 218 former or current smokers (aged 40–85 years) with COPD on inhaled background therapy (2:1) to dupilumab 300 mg or placebo every 2 weeks for 24 weeks. Key inclusion criteria were post-bronchodilator forced expiratory volume in 1 s (FEV 1 ) to forced vital capacity ratio <0.70, FEV 1 30% predicted to <80% pred, screening blood eosinophil count ≥300 cells·μL −1 or ≥150 cells·μL −1 with a history of ≥300 cells·μL −1 in the previous year, two or more moderate exacerbations or one or more severe exacerbations in the previous year and mucus plug score ≥3 on computed tomography (CT). The primary end-point was week 24 change from baseline in CT-evaluated mucus plug score. Secondary end-points were week 24 change from baseline in mucus plug volume, distal airway wall thickness, oscillometry parameters and safety. Conclusion AEOLUS will evaluate the effect of dupilumab on airway characteristics (mucus, resistance and remodelling) in patients with COPD and type 2 inflammation.

ERJ Open Research
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon